Li Jixin, Wang Hui, Zhang Siyang, Quan Linru, Zhou Xin
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Front Genet. 2024 Oct 8;15:1466422. doi: 10.3389/fgene.2024.1466422. eCollection 2024.
Ovarian cancer is the most mortality malignancy in gynecology. N7-methylguanosine (m7G) is one of the most prevalent RNA modifications in the development and progression of cancer. The aim of this study is to investigate the effect of m7G-related lncRNA on ovarian cancer in terms of instruction prognosis and immunotherapy.
After integrating and processing the RNA expression profiles with the clinical sample information in the TCGA database, we initially screened to the m7G-related lncRNAs by Spearman correlation analysis, and subsequently obtained a prognostic model constructed by five m7G-related lncRNAs with Univariate Cox analysis, LASSO regression analysis, and Multivariate Cox regression analysis, after which we further evaluated and validated the prognostic value of the model using Kaplan-Meier survival analysis, Principal component analysis, Nomogram, and ROC curve. In addition, based on this risk model, we explored the differentially enriched pathways and functions of the high and low risk groups, and characterized the immune cells, immune functions, gene mutations, and drug sensitivity between the two groups.
After a series of rigorous filtering, we finally attained a prognostic risk model consisting of KRT7-AS, USP30-AS1, ZFHX4-AS1, ACAP2-IT1, and TWSG1-DT which is excellent in predicting the prognostic survival of ovarian cancer patients as well as existing as an independent prognostic factor. Moreover, the model has certain relevance in the immune cells and functions between high and low risk groups, and simultaneously, the signature has the role of guiding the option of immunotherapy and chemotherapeutic drugs.
Altogether, our study established a tight connection between m7G-associated lncRNAs and ovarian cancer, with potential that the prognostic patterns contribute to steering the prognosis of ovarian cancer patients, measuring the efficacy of immunotherapeutic approaches, and detecting effective chemotherapeutic agents.
卵巢癌是妇科最致命的恶性肿瘤。N7-甲基鸟苷（m7G）是癌症发生发展过程中最普遍的RNA修饰之一。本研究旨在探讨m7G相关长链非编码RNA在卵巢癌预后和免疫治疗方面的作用。
将RNA表达谱与TCGA数据库中的临床样本信息进行整合和处理后，通过Spearman相关性分析初步筛选出m7G相关长链非编码RNA，随后经单因素Cox分析、LASSO回归分析和多因素Cox回归分析，获得由5个m7G相关长链非编码RNA构建的预后模型，之后使用Kaplan-Meier生存分析、主成分分析、列线图和ROC曲线进一步评估和验证该模型的预后价值。此外，基于此风险模型，我们探索了高风险组和低风险组差异富集的通路和功能，并对两组之间的免疫细胞、免疫功能、基因突变和药物敏感性进行了表征。
经过一系列严格筛选，我们最终获得了一个由KRT7-AS、USP30-AS1、ZFHX4-AS1、ACAP2-IT1和TWSG1-DT组成的预后风险模型，该模型在预测卵巢癌患者的预后生存方面表现出色，并且是一个独立的预后因素。此外，该模型在高风险组和低风险组的免疫细胞和功能方面具有一定相关性，同时，该特征对免疫治疗和化疗药物的选择具有指导作用。
总之，我们的研究建立了m7G相关长链非编码RNA与卵巢癌之间的紧密联系，预后模式有可能用于指导卵巢癌患者的预后、评估免疫治疗方法的疗效以及检测有效的化疗药物。
